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Abstract
Background: The purported value of empirical therapy to cover methicillin-resistant Staphylococcus aureus (MRSA)
has been debated for decades. The purpose of this study was to evaluate the effects of inappropriate empirical
antibiotic therapy on clinical outcomes in patients with healthcare-associated MRSA bacteremia (HA-MRSAB).
Methods: A prospective, multicenter, observational study was conducted in 15 teaching hospitals in the Republic
of Korea from February 2010 to July 2011. The study subjects included adult patients with HA-MRSAB. Covariate
adjustment using the propensity score was performed to control for bias in treatment assignment. The predictors
of in-hospital mortality were determined by multivariate logistic regression analyses.
Results: In total, 345 patients with HA-MRSAB were analyzed. The overall in-hospital mortality rate was 33.0 %.
Appropriate empirical antibiotic therapy was given to 154 (44.6 %) patients. The vancomycin minimum inhibitory
concentrations of the MRSA isolates ranged from 0.5 to 2 mg/L by E-test. There was no significant difference in
mortality between propensity-matched patient pairs receiving inappropriate or appropriate empirical antibiotics
(odds ratio [OR] = 1.20; 95 % confidence interval [CI] = 0.71–2.03). Among patients with severe sepsis or septic shock,
there was no significant difference in mortality between the treatment groups. In multivariate analyses, severe
sepsis or septic shock (OR = 5.45; 95 % CI = 2.14–13.87), Charlson’s comorbidity index (per 1-point increment; OR = 1.
52; 95 % CI = 1.27–1.83), and prior receipt of glycopeptides (OR = 3.24; 95 % CI = 1.08–9.67) were independent risk
factors for mortality.
Conclusion: Inappropriate empirical antibiotic therapy was not associated with clinical outcome in patients with
HA-MRSAB. Prudent use of empirical glycopeptide therapy should be justified even in hospitals with high MRSA
prevalence.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) has
been a major cause of healthcare-associated bacteremia
[1, 2]. MRSA bacteremia (MRSAB), with a mortality rate
as high as 40 %, is a grave concern because a clinical
cure may not be achieved using standard therapy in
some cases [3–6]. Evidence-based therapy and the iden-
tification of mortality-related risk factors for MRSAB
continue to represent significant clinical challenges for
clinicians.
Previous studies determined the independent predictors
of mortality among patients with MRSAB, including old
age (≥60 years), underlying cardiac diseases, a higher
Charlson’s comorbidity index, pneumonia, septic shock,
metastatic infection, non-eradicable foci, and higher
vancomycin minimum inhibitory concentrations (MICs)
of the MRSA isolates [7–9]. However, studies evaluating
the presence of relationships between clinical outcome
and inappropriate empirical antibiotic therapies in
patients with MRSAB have yielded conflicting results
[10–16]. The conflicting results on the benefits of early
empirical antibiotic therapy are probably due to differing
definitions of “inappropriate” therapy on the basis of in
vitro susceptibility data, impact of potentially confounding
variables, and selection or information biases such as the
baseline severity of illness [17, 18]. The definition and cri-
teria items used to denote the appropriate antibiotic ther-
apy should include the criterion matching the in vitro
susceptibility and the timing of the administration of the
antibiotics as well as their optimal dose and usage [19, 20].
A recent meta-analysis involving 510 MRSAB episodes
demonstrated an overall 2-fold increased survival benefit
with the administration of appropriate empirical therapy
for MRSAB episodes, but there are some problems with
heterogeneity across the studies [21]. In the meanwhile,
the prudent use of glycopeptides has been an import-
ant component of hospital antimicrobial stewardship
programs to contain the emergence of glycopeptide
resistance, especially in high-prescribing countries
with a high prevalence of MRSA. Thus, empirical
glycopeptides use for MRSAB should be guided on
the basis of scientific data.
The purpose of this study was to assess the influence
of inappropriate empirical antimicrobial therapy on
mortality in patients with healthcare associated-MRSAB
(HA-MRSAB) in a hospital setting in which the preva-
lence of MRSA was high.
Methods
Study design and setting
A prospective, multi-center, observational study was
conducted to compare clinical outcomes between patients
receiving inappropriate or appropriate antibiotics for the
treatment of HA-MRSAB in 15 teaching hospitals in the
Republic of Korea from February 2010 to July 2011. This
cross-sectional study was performed in accordance with
the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) guidelines. Two analytical
strategies were used: (1) for the non-matched case–con-
trol study (n = 345), the clinical outcomes of 154 patients
who received appropriate empirical antibiotic treatment
was compared with those of 191 patients who received
inappropriate treatment; and (2) for the propensity score-
matched (1:1) case–control study, the outcome was
compared between 127 pairs of patients who received
inappropriate or appropriate empirical antibiotics. Cases
were defined as the patients treated with inappropriate
empirical antibiotics, and controls were defined as those
with HA-MRSAB who were treated with appropriate
empirical antibiotics. The primary endpoint was all-cause
in-hospital mortality. The secondary endpoints were
mortality attributable to MRSAB, persistent fever, and
persistent MRSAB.
All 15 participating hospitals have long had a high
prevalence of MRSA, which accounted for about
approximately 70 % of all S. aureus isolates. Clinical data
were collected at each participating site via a standardized
web-based case report form. A representative infectious
disease specialist from each site prospectively reviewed
and interpreted clinical data for the enrolled patients. A
trough serum concentration of vancomycin was measured
routinely in 13 of the 15 participating hospitals in this
study.
Study population
Study subjects included hospitalized adult patients
(aged ≥18 years) with HA-MRSAB who had ≥1 positive
blood culture for MRSA. Our study excluded the subjects
who did not receive the active antibiotics against MRSA,
after confirming that the index blood culture was positive
for MRSA. All patients were followed up until death or
hospital discharge. If a patient had more than 1 episode of
HA-MRSAB during the study period, only the first epi-
sode was included. Patients with polymicrobial bacteremia
were excluded from the analysis specifically evaluating the
influence of empirical antimicrobial therapy for HA-
MRSAB. Physicians treated patients according to routine
medical practices without standardized protocols of
intervention.
Definitions
Patients with healthcare-associated or nosocomial
MRSAB were included in this study. MRSAB diagnosed
within 48 h of hospital admission was considered
healthcare-associated infection, if the patient met any
healthcare-associated criteria in the preceding 3 months,
including admission to a hospital, nursing home, or
other healthcare facility for more than 2 days, specialized
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home care, treatment at a medical day unit, surgery,
dialysis, or permanent indwelling catheters. MRSAB
diagnosed after 48 h of hospital admission was consid-
ered nosocomial infection.
The primary focus of HA-MRSAB was determined by
the organ affected and classified as follows: catheter-related
bloodstream infection (CR-BSI) [22], lower respiratory
tract, intra-abdominal, urinary tract, skin and soft tissue,
bone and joint, or central nervous system infection; or
unknown when no other site of infection was evident [23].
Sepsis, severe sepsis, and septic shock were diagnosed in
accordance with standard criteria [24].
Definitive therapy was defined as the antibiotic therapy
administered subsequent to the receipt of the final blood
culture and antibiotic susceptibility results [17]. Empir-
ical antibiotic therapy was defined as initial antibiotic
treatment started before the pathogen was identified and
antimicrobial susceptibility test results were obtained.
Empirical antibiotic therapy was defined as appropriate
if the pathogen was shown in in vitro studies to be sus-
ceptible to the antibiotic administered intravenously
with optimal dosing and if the timing of administration
was within 48 h of obtaining the index positive blood
culture. If it did not meet any of these criteria, it was
regarded as inappropriate antibiotic therapy. Prior anti-
biotic exposure was defined as the receipt of >3 doses of
antibiotics within 3 months before the occurrence of
HA-MRSAB. The duration of bacteremia after definitive
antibiotic therapy was calculated as the number of days
from initiation of definitive antibiotic treatment against
HA-MRSAB to the day on which the first negative blood
culture was obtained.
Mortality attributable to MRSA bacteremia was
defined as death with positive blood cultures for MRSA
and persistent fever, but no other definitive causes of
death. Persistent MRSAB and persistent fever were
defined as positive blood cultures for MRSA for ≥7 days
and as a fever ≥38.0 °C for ≥7 days after the commence-
ment of appropriate antibiotic treatment, respectively.
Variables
The clinical data of patients were extracted from medical
records, including age, gender, medical history, comor-
bid medical conditions, Charlson’s comorbidity index
[25], primary site of infection, risk factors predisposing
to infections within 3 months before the occurrence of
HA-MRSAB, APACHE II scores [26], Pitt’s bacteremia
score [27] on the day of index positive blood culture
sampling, presence of severe sepsis or septic shock, mor-
tality attributable to MRSAB, and in-hospital mortality.
Microbiological tests
The identification of MRSA and antibiotic susceptibility
tests were performed in each hospital using the MicroScan
Pos Combo Panel Type 6 automated system (Baxter
Diagnostics, West Sacramento, CA, USA) or VITEK II
automated system (bioMérieux, Hazelwood, MO, USA).
All MRSA isolates from index blood cultures were col-
lected at the coordinating center and immediately stored
at −70 °C until August 2012 when the MICs of vanco-
mycin were further determined by the E-test (bioMérieux,
Marcy l’Etoile, France) according to the manufacturer’s
instructions.
Statistical analysis
Categorical variables were denoted as count (proportion)
and compared using Pearson’s chi-squared test, Fisher’s
exact test, or McNemar’s test. Continuous variables were
expressed as the mean ± standard deviation or median
(inter-quartile range [IQR]) and compared using two-
sample Student’s t-tests, the Mann–Whitney U test, or
Wilcoxon’s signed-rank test. All tests were two-tailed, and
a P-value <0.05 was considered statistically significant.
For the covariate adjustment between patients receiv-
ing inappropriate or appropriate empirical antibiotic
therapy, variables that represented the probability of
being treated inadequately were found. In univariate
analysis of 345 patients with HA-MRSAB, baseline and
clinical characteristics were compared between the two
treatment groups. Variables at the 10 % significance level
were considered independent variables for the propen-
sity scores, including category of infection, trauma, pri-
mary focus of HA-MRSAB (such as CR-BSI, pneumonia,
or urinary tract infection), severe sepsis or septic shock,
infective endocarditis, retention of foreign body, surgery,
and recent exposure to immunosuppressive agents such
as systemic corticosteroids on a regular basis or antineo-
plastic chemotherapy, third-generation cephalosporins,
or fluoroquinolones during the preceding 30 days.
Patients who received inappropriate empirical antibiotic
therapy were matched 1:1 with patients who received
appropriate empirical antibiotic therapy with regard
to 5 digits of the propensity score without replacement
[28, 29]. To confirm whether we had a good match, the
absolute standardized differences for each covariate in the
model and distribution of propensity scores were evalu-
ated [30]. To determine the predictors of in-hospital mor-
tality in patients with HA-MRSAB, multivariate
conditional logistic regression analyses within the
matched data set were performed with all variables
with a P-value ≤0.10 in the univariate analysis as well
as the main variable of inappropriate empirical anti-
biotic therapy.
Within the unmatched data set, inverse probability of
treatment weighting (IPTW) based on the propensity
score was also used to control for bias in treatment
assignment [30, 31].
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Data were analyzed using IBM SPSS Statistics version
20.0 (IBM Corporation, Armonk, NY, USA), R 2.15.2
(The R Foundation for Statistical Computing, Vienna,
Austria), and SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
During the study period, a total of 345 patients with
HA-MRSAB were included in our analysis. Their demo-
graphic and clinical characteristics are presented in
Table 1. The most common primary focus of HA-MRSAB
was CR-BSI (51.3 %), followed by pneumonia (11.6 %),
surgical wound infection (7.0 %), intra-abdominal infec-
tion (21.0 %), skin and soft tissue infection (4.9 %), and
others (4.2 %). The all-cause in-hospital mortality and
MRSAB-related mortality rates were 33.0 (114/345) and
16.5 % (57/345), respectively. An in-hospital mortality rate
of at least 25 % was noted for pneumonia (55 %), central
nervous system infections, MRSAB of unknown origin
(44.4 %), intra-abdominal infections (38.1 %), CR-BSI
(33.3 %), and cardiovascular infections (28.6 %), whereas
mortality rates of less than 25 % were observed for urinary
tract infections, surgical wound infections, skin and soft
tissue infections, bone and joint infections, and head and
neck infections. Six patients died before the culture results
were reported as follows: 4 patients presented with septic
shock and 2 patients displayed high APACHE II scores of
30 and 39, respectively.
Of the 345 patients with HA-MRSAB, 154 (44.6 %)
patients received appropriate empirical antibiotic therapy.
The antibiotics used for definitive therapy were vancomycin
Table 1 Demographic and clinical characteristics of 345 patients with healthcare-associated methicillin-resistant Staphylococcus aureus
bacteremia according to the appropriateness of initial empirical antimicrobial therapy
Variables All (n = 345) Appropriate
(n = 154, 44.6 %)
Inappropriate
(n = 191, 55.4 %)
Odds ratio (95 %
confidence interval)
Male sex 154 (44.6) 97 (43.9) 124 (56.1) 0.92 (0.59–1.43)
Age (years), median (IQR) 67 (52–75) 66 (51–74) 67 (53–75) 0.99 (0.98–1.01)
Category of infection
Healthcare-associateda 51 (14.8) 29 (18.8) 22 (11.5) 1.78 (0.98–3.25)
Nosocomial 294 (85.2) 125 (81.2) 169 (88.5)
Comorbidity
Malignancy 97 (28.1) 47 (30.5) 50 (26.2) 0.81 (0.50–1.29)
Metabolic 122 (35.4) 52 (33.8) 70 (36.6) 1.14 (0.73–1.77)
Trauma 29 (8.4) 10 (6.5) 19 (9.9) 1.59 (0.72–3.53)
Charlson’s comorbidity indexb, median (IQR) 2 (1–4) 2 (1–5) 2 (1–4) 1.09 (1.00–1.20)
Primary focus of HA-MRSAB
CR-BSI 177 (51.3) 93 (60.4) 84 (44.0) 0.52 (0.34–0.79)
Pneumonia 40 (11.6) 13 (8.4) 27 (14.1) 1.79 (0.89–3.59)
Clinical severity
Development of severe sepsis or septic shock 99 (28.7) 50 (32.5) 49 (25.7) 0.72 (0.45–1.15)
Pitt’s bacteremia score at onset of bacteremiac, median (IQR) 1 (0–2) 1 (0–3) 1 (0–2) 1.08 (0.96–1.21)
Predisposing factors
Surgical operation 84 (24.3) 29 (18.8) 55 (28.8) 1.74 (1.05–2.91)
Foreign body retention 15 (4.3) 12 (7.8) 3 (1.6) 0.189 (0.05–0.69)
Prior antibiotics use 219 (63.5) 99 (64.3) 120 (62.8) 0.94 (0.60–1.46)
Vancomycin MIC, mg/L 1 (1–1.5) 1 (1–1.5) 1 (1–1.5) 1.57 (0.81–3.04)
Outcomes
In-hospital mortality 114 (33.0) 51 (33.1) 63 (33.0) 0.99 (0.63–1.56)
MRSAB-related mortality 57 (16.5) 24 (15.6) 33 (17.3) 1.13 (0.64–2.01)
IQR interquartile range, APACHE acute physiology and chronic health evaluation, CR-BSI catheter-related bloodstream infection, MIC minimum inhibitory
concentration, MRSAB methicillin-resistant Staphylococcus aureus bacteremia
aMRSAB diagnosed within 48 h of hospital admission was considered healthcare-associated infection, if the patient presented with any healthcare-associated
factor in the preceding 3 months
bCharlson’s comorbidity score was calculated at the onset of MRSA bacteremia infection
cPitt’s bacteremia score and APACHE II scores were assessed at the onset of MRSA bacteremia
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(n = 201, 58.3 %), teicoplanin (n = 96, 27.8 %), arbekacin
(n = 63, 18.3 %), linezolid (n = 34, 9.9 %), and tigecyc-
line (n = 8, 2.3 %). Combination antibiotic therapy was
administered to 15 patients as follows: glycopeptides
plus rifampin (n = 11), linezolid plus arbekacin (n = 2),
tigecycline plus arbekacin (n = 1), and teicoplanin plus
arbekacin (n = 1).
For the non-matched case–control study (n = 345), the
clinical outcomes of 154 patients who received appropri-
ate empirical antibiotic therapy was compared with those
of 191 patients who received inappropriate therapy. There
were no significant differences in in-hospital mortality
(odds ratio [OR] = 0.99; 95 % confidence interval [CI] =
0.63–1.56) or MRSAB-related mortality (OR = 1.13; 95 %
CI = 0.64–2.01) between the two treatment groups
(Table 1).
Propensity score-matched analysis
For the propensity score-matched (1:1) case–control
study, only 127 patient pairs were matched according to
the propensity score, because some variables, namely
catheter-related bloodstream infection, retention of for-
eign body, surgical operation, and Charlson’s comorbidity
index, showed large differences between the two groups.
Comparisons of demographic, clinical, and microbio-
logical characteristics between the propensity-matched
127 pairs receiving inappropriate or appropriate empirical
antibiotics are shown in Table 2. There were no significant
differences in in-hospital mortality (OR = 1.20; 95 % CI =
0.71–2.03) or MRSAB-related mortality (OR = 1.34; 95 %
CI = 0.68–2.62) between the two treatment groups
(Table 2). The antibiotics used for the appropriate empir-
ical antibiotic therapy were vancomycin (n = 93, 73.2 %),
teicoplanin (n = 22, 17.3 %), and arbekacin (n = 12, 9.4 %).
To assess the effect of empirical antibiotic therapy
according to the clinical severity of HA-MRSAB, the
clinical outcomes of patients with HA-MRSAB in associ-
ation with empirical antibiotic therapy and the severity
of HA-MRSAB were analyzed (Table 3). For the sub-
group with severe sepsis (n = 75), septic shock (n = 45),
or a higher Charlson’s comorbidity index (≥3) (n = 108),
there were no significant differences in either in-hospital
mortality or MRSAB-related mortality between the pa-
tients receiving inappropriate or appropriate empirical
antibiotic treatment (Table 3).
The covariate balance of independent variables for the
propensity scores between the unmatched and matched
data sets is presented in Table 4. In the propensity score-
matched analysis, matched standardized differences
should be less than 0.20 and preferably 0.10 for the
balanced distribution of the relevant variables between the
two groups [32, 33]. Figure 1 demonstrates graphic
overlays of distribution of the propensity scores before
and after matching between the two treatment groups.
The factors associated with all-cause in-hospital mor-
tality in patients with HA-MRSAB were determined in
the propensity score-matched set. For the 254 patients
included, demographic, clinical, and microbiological
characteristics were compared between 84 non-survivors
and 170 survivors (Table 2).
In multivariate conditional logistic regression analysis,
severe sepsis or septic shock (OR = 5.45; 95 % CI = 2.14–
13.87), Charlson’s comorbidity index (per 1-point incre-
ment; OR = 1.52; 95 % CI = 1.27–1.83), and prior receipt
of glycopeptides (OR = 3.24; 95 % CI = 1.08–9.67) were
found to be independent risk factors for in-hospital
mortality (Table 5).
As shown in Table 6, in multivariate logistic regression
models of risk factors for in-hospital mortality using
naïve, propensity score matching, or IPTW approaches,
inappropriate empirical antibiotic therapy was not an
independent predictor for mortality (Table 6).
Microbiological factors and clinical outcomes
A total of 296 (85.8 %) MRSA isolates were available for
analyzing vancomycin MICs using the E- test. The
measured vancomycin MIC range was 0.5–2 mg/L;
vancomycin MIC50 and MIC90 were both 1.5 mg/L.
There was no difference in mortality outcomes between
the two groups categorized as each reference cut-off of
vancomycin MICs: ≥1.0 mg/L (OR = 1.76; 95 % CI =
0.36–8.71), ≥1.5 mg/L (OR = 1.60; 95 % CI = 0.91–2.83)
and ≥2.0 mg/L (OR = 2.46; 95 % CI = 0.95–6.34)
(Table 2).
Discussion
This propensity-matched study investigated the impact
of inappropriate empirical antibiotic therapy on mortal-
ity after adjusting for potentially confounding factors
that influence the receipt of inappropriate empirical
antibiotic therapy in patients with HA-MRSAB in hospi-
tals with a high prevalence of MRSA. This study found
that an initial delay in the use of definitive antibiotics to
which the MRSA isolates were susceptible did not ne-
cessarily prejudice the clinical outcomes of patients with
HA-MRSAB and that the impetuous use of glycopeptide
as empirical therapy targeting MRSA isolates should be
moderated in terms of increasing antibiotic resistance.
Although initial empirical broad-spectrum antibiotic
therapy, sometimes involving combination treatment, in
bacteremic patients may appear to be an attractive
treatment strategy before microbiological results are
available, it can lead to increases in antibiotic resistance,
costs, and adverse events. Studies investigating the
association between inappropriate empirical antibiotic
therapy and mortality among patients with bloodstream
infections have reported conflicting findings. Thirteen
studies have assessed the effects of empirical antibiotic
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Table 2 Comparison of clinical and microbiological characteristics and outcomes among patients with healthcare-associated
methicillin-resistant Staphylococcus aureus bacteremia according to the appropriateness of empirical antibiotic therapy or
treatment outcome in the propensity-matched analyses





OR (95 % CI) Non-survival
(n = 81, 31.9 %)
Survival
(n = 173, 68.1 %)
OR (95 % CI)
Male sex 165 (65.0) 84 (66.1) 81 (63.8) 1.03 (0.62–1.72) 59 (70.2) 106 (62.4) 0.66 (0.38–1.15)
Age (years), median (IQR) 67 (52–75) 68 (53–76) 65 (51–73) 0.99 (0.97–1.00) 72 (60–79) 63 (48–72) 1.03 (1.01–1.05)
Category of infection
Healthcare-associateda 32 (12.6) 16 (12.6) 16 (12.6) 1.07 (0.52–2.23) 4 (4.8) 28 (16.5) 2.31 (0.91–5.84)
Nosocomial 222 (87.4) 111 (87.4) 111 (87.4) 80 (95.2) 142 (83.5)
Comorbidity
Malignancy 68 (26.8) 30 (23.6) 38 (29.9) 0.66 (0.37–1.16) 33 (39.3) 35 (20.6) 2.63 (1.46–4.73)
Trauma 24 (9.4) 14 (11.0) 10 (7.9) 1.33 (0.56–3.17) 7 (8.3) 17 (10.0) 0.93 (0.37–2.35)
Charlson’s comorbidity indexb, median (IQR) 2 (1–4) 2 (1–4) 2 (1–4) 1.08 (0.97–1.19) 3 (2–6) 2 (0–2) 1.37 (1.21–1.54)
Predisposing factors
Foreign body retention 4 (1.6) 2 (1.6) 2 (1.6) 1.00 (0.14–7.21) 1 (1.2) 3 (1.8) 0.71 (0.07–6.92)
Surgical operation 48 (18.9) 24 (18.9) 24 (18.9) 1.00 (0.53–1.87) 14 (16.7) 34 (20.0) 1.09 (0.56–2.12)
Prior antibiotic use 151 (59.4) 73 (57.5) 78 (61.4) 1.00 (0.60–1.66) 58 (69.0) 93 (54.7) 2.39 (1.33–4.30)
Third-generation cephalosporins 78 (30.7) 40 (31.5) 38 (29.9) 1.15 (0.68–1.95) 27 (32.1) 51 (30.0) 1.40 (0.81–2.44)
Fluoroquinolones 39 (15.4) 17 (113.4) 22 (17.3) 0.89 (0.45–1.75) 16 (19.8) 23 (13.5) 1.96 (0.99–3.91)
Glycopeptides 36 (14.2) 14 (11.0) 22 (17.3) 0.77 (0.38–1.57) 19 (22.6) 17 (10.0) 2.15 (1.05–4.41)
Primary focus of HA-MRSAB
CR-BSI 144 (56.7) 72 (56.7) 72 (56.7) 1.03 (0.63–1.70) 52 (61.9) 92 (54.1) 1.03 (0.61–1.75)
Pneumonia 22 (8.7) 12 (9.4) 10 (7.9) 0.41 (0.62-3.21) 11 (13.1) 11 (6.5) 3.35 (1.46–7.67)
Clinical severity
Development of severe sepsis or septic shock 75 (29.5) 33 (26.0) 42 (33.1) 0.64 (0.37–1.09) 43 (51.2) 32 (18.8) 5.24 (2.93–9.38)
Pitt’s bacteremia scorec, median (IQR) 1 (0–3) 1 (0–3) 1 (0–3) 1.08 (0.94–1.24) 3 (1–4) 1 (0–2) 0..96 (0.82–1.12)
Vancomycin MIC, mg/L
MIC ≥1.0 mg/L 211 (96.3) 106 (98.1) 105 (94.6) 1.15 (0.52–2.54) 69 (95.8) 142 (96.6) 1.76 (0.36–8.71)
MIC ≥1.5 mg/L 94 (42.9) 39 (36.1) 55 (49.5) 0.60 (0.31–1.16) 34 (47.2) 60 (40.8) 1.60 (0.91–2.83)
MIC ≥2 mg/L 19 (8.7) 8 (7.4) 11 (9.9) 0.47 (0.08–2.61) 9 (12.5) 10 (6.8) 2.46 (0.95–6.34)
Appropriate empirical antibiotic therapy, n (%) 127 (50.0) 42 (50.0) 85 (50.0) 1.20 (0.71–2.03)
Definitive therapy
Vancomycin 145 (57.1) 68 (53.5) 77 (60.6) 0.75 (0.46–1.23) 48 (57.1) 97 (57.1) 1.00 (0.59–1.70)
Teicoplanin 75 (29.5) 38 (29.9) 37 (29.1) 1.04 (0.61–1.78) 26 (31.0) 49 (28.8) 1.11 (0.63–1.96)
Linezolid 28 (11.0) 16 (12.6) 12 (9.4) 1.38 (0.63–3.05) 9 (10.7) 19 (11.2) 0.95 (0.41–2.21)
Arbekacin 45 (17.7) 25 (19.7) 20 (15.7) 1.31 (0.69–2.51) 10 (11.9) 35 (20.6) 0.52 (0.24–1.11)
Tigecycline 4 (1.6) 2 (1.6) 2 (1.6) 1.00 (0.14–6.99) 2 (2.4) 2 (1.2) 2.05 (0.28–14.80)
Rifampind 9 (3.5) 7 (5.5) 2 (1.6) 3.65 (0.74–17.9) 0 9 (5.3) 0.95 (0.91–0.98)
Outcomes
In-hospital mortality 84 (33.1) 42 (33.1) 42 (33.1) 1.20 (0.71–2.03) 1.20 (0.71–2.03)
MRSAB-related mortality 40 (15.7) 21 (16.5) 19 (15.0) 1.34 (0.68–2.62) 40 (47.6) 0 2.03 (1.62–2.53)
CR-BSI catheter-related bloodstream infection, IQR interquartile range, MIC minimum inhibitory concentration, MRSA methicillin-resistant Staphylococcus aureus,
MRSAB methicillin-resistant Staphylococcus aureus bacteremia
aMRSAB diagnosed within 48 h of hospital admission was considered healthcare-associated infection, if the patient presented with healthcare-associated factor in
the preceding 3 months
bCharlson’s comorbidity index was calculated at the first identification of MRSA bloodstream infection
cPitt’s bacteremia score was assessed at the first identification of MRSA bloodstream infection
dRifampin, which was prescribed in the survivals for the maintenance combination treatment during the finishing step for the small number of study cases
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therapy on mortality in study populations with MRSAB
[10–16, 21, 34–36]. Seven of these study demonstrated
that timely empirical therapy for MRSAB was associated
with reduced mortality [10, 12–14, 21, 35, 36]. By
contrast, six other studies reported an opposite result
[11, 15, 16, 19, 20, 34]. Interestingly, three studies
conducted in Asia reported that an initial delay in the use
of definitive antibiotics to which the MRSA isolates were
susceptible did not have a detrimental effect on mortality
[11, 19, 20]. Paul et al. [21] speculated that the studies did
not confirm an advantage to empirical vancomycin treat-
ment, as the prevalence of vancomycin MICs >1.5 mg/L
might be higher in Asia than in other locations [7, 9, 37–39].
On the contrary, a lack of agreement in the association
between appropriate antibiotic therapy and mortality in
bacteremic patients among the previous studies might
be attributable to methodological heterogeneity. Appropri-
ate antibiotic therapy and mortality were not consistently
measured, and significant confounding variables were not
always considered in the final analysis [17]. Therefore, in
the present study on patients with HA-MRSAB, we obvi-
ously defined the appropriateness of antibiotic therapy in
terms of its in vitro activity against the MRSA isolates, the
timing and routes of administration, and the doses of the
prescribed antibiotics; we also defined empirical and defini-
tive antibiotic therapy clearly. We conducted multivariate
analysis to adjust for confounding variables, including clin-
ical severity and patients’ comorbidity at the onset of HA-
MRSAB. Although the previous studies used a multivariate
logistic regression analyses, residual confounding associ-
ated with the choice of appropriate or inappropriate
Table 3 Comparison of in-hospital mortality rates according to the clinical severity of healthcare-associated methicillin-resistant
Staphylococcus aureus bacteremia in the propensity-matched analyses
Empirical antibiotic therapy In-hospital mortality, n (%) OR (95 % CI) MRSA-related mortality, n (%) OR (95 % CI)
Severe sepsis or septic shock (n = 75)
Yes Appropriate 24 (57.1) 1.02 (0.41–2.56) 13 (31.0) 1.12 (0.42–2.96)
Inappropriate 19 (57.9) 11 (33.3)
No Appropriate 18 (21.2) 1.21 (0.60–2.43) 6 (7.1) 1.57 (0.54–4.51)
Inappropriate 23 (24.5) 10 (10.6)
Septic shock (n = 45)
Yes Appropriate 20 (66.7) 1.00 (0.27–3.72) 12 (40.0) 1.00 (0.28–3.54)
Inappropriate 10 (66.7) 6 (40.0)
No Appropriate 22 (22.7) 1.36 (0.73–2.55) 7 (7.2) 1.99 (0.78–5.10)
Inappropriate31 32 (28.6) 15 (13.4)
Charlson’s comorbidity index ≥3 (n = 108)
Yes Appropriate 31 (56.4) 0.62 (0.29–1.32) 13 (23.6) 0.83 (0.33–2.05)
Inappropriate 24 (44.4) 11 (20.8)
No Appropriate 11 (15.3) 1.82 (0.79–4.18) 6 (8.3) 1.75 (0.60–5.09)
Inappropriate 18 (24.7) 10 (13.7)
MRSA methicillin-resistant Staphylococcus aureus
Table 4 Covariate balance of independent variables for the







Nosocomial infection 20.49 0.00
Trauma 12.60 10.78
Surgical operation 23.56 0.00
Immunosuppressive agents 15.43 10.73
Prior exposure to third-generation
cephalosporins
11.91 3.41
Prior exposure to fluoroquinolones 12.36 10.94
Prior exposure to glycopeptides 14.06 18.14
CR-BSI 33.30 0.00
Pneumonia 18.07 5.60
Urinary tract infection 19.90 18.11
Severe sepsis or septic shock 15.05 15.58
Retention of foreign body 29.78 0.00
Infective endocarditis 15.25 18.11
Charlson’s comorbidity index 21.35 16.12
Pitt’s bacteremia score 13.35 11.08
Age 10.47 13.89
Vancomycin MICs 15.67 17.59
CR-BSI catheter-related bloodstream infection,MICminimum inhibitory concentration
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empirical antibiotics was not fully excluded. Thus, our
propensity-matched analysis calibrated all covariates that
affect both the outcome and treatment assignment be-
tween patients who received appropriate and inappropriate
empirical antibiotics.
In this study, there was no significant difference in
mortality between the 127 pairs of propensity-matched
patients who received inappropriate or appropriate
empirical antibiotics. These results were comparable
with the findings from a study by Kim et al. using a
propensity score [20]. Among 345 patients with HA-
MRSAB analyzed in our study, empirical antibiotic
therapy against MRSA isolates was given to 154 (44.6 %)
patients. It was previously described that infections due
to gram-positive organisms do not have a rapid
course, unlike those caused by gram-negative pathogens
[40, 41]. In two meta-analyses of febrile neutropenic
patients, there was no statistically significant differ-
ence in mortality between those who received a
glycopeptide as part of the empirical regimen and
those who did not receive glycopeptides [42, 43]. In
addition, a large retrospective review from the
National Cancer Institute suggested that the addition
of vancomycin can be delayed until after four days of
antibiotic monotherapy against Pseudomonas aerugi-
nosa without any resulting increase in morbidity or
mortality, even when a gram-positive infection was
proven [44, 45].
Fig. 1 The distribution of propensity scores in unmatched and matched data sets for the appropriate empirical antibiotic treatment (a) and
inappropriate empirical antibiotic treatment groups (b)
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In this study, the in-hospital mortality rate of HA-
MRSAB was 33.1 %, which is comparable to the range
from 29 % to 45 % reported in other studies [10, 12, 16,
36]. Within our propensity score-matched data set, three
prognostic factors were associated with in-hospital
mortality in patients with HA-MRSAB: severe sepsis or
septic shock, Charlson’s comorbidity index at the onset
of HA-MRSAB, and prior receipt of glycopeptides.
These findings were similar to those of other studies
[11–15, 20, 21]. In particular, prior exposure to glyco-
peptides was reported as an independent predictor of
treatment failure for MRSAB in several studies [12, 13,
15, 20, 21]. This fact strengthens the hypothesis that the
empirical use of glycopeptides should be judicious even
in patients suspected to have MRSAB. In addition, a
higher vancomycin MIC has been recognized as one of
the predictors associated with increased mortality and
treatment failure among patients with MRSAB [46, 47].
Prior exposure to glycopeptides is likely to be associated
with mortality in patients with MRSAB, as recent
exposure to vancomycin may lead to increased vanco-
mycin MICs [48]. In this study, we failed to identify a
significant impact of higher vancomycin MIC values on
mortality in patients with HA-MRSAB, probably due to
use of several antibiotics with activity against MRSAB.
Vancomycin was used as a definite antibiotic in
58.3 % of the 345 patients with HA-MRSAB analyzed
in the study.
Table 5 Multivariate conditional logistic regression analysis of risk factors for in-hospital mortality in patients with healthcare-associated




(IPTW, n = 345)
Matched data set
(n = 254)
Independent variable OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Inappropriate empirical antibiotic therapy 1.26 (0.64–2.48) 0.499 1.33 (0.83–2.12) 0.236 NAa 0.988
Nosocomial infection 2.24 (0.87–5.80) 0.096 2.62 (1.28–5.37) 0.009
Trauma 0.60 (0.18–1.97) 0.398 0.66 (0.28–1.52) 0.329 1.95 (0.50–7.56) 0.335
Surgical operation 1.20 (0.54–2.66) 0.656 1.22 (0.69–2.17) 0.493
Prior exposure to third- generation cephalosporins 1.34 (0.68–2.63) 0.399 1.23 (0.76–2.00) 0.407 0.93 (0.41–2.10) 0.853
Prior exposure to fluoroquinolones 0.51 (0.22–1.22) 0.129 0.66 (0.35–1.24) 0.193 1.24 (0.44–3.51) 0.683
Prior exposure to glycopeptides 2.85 (1.20–6.77) 0.018 2.86 (1.55–5.28) 0.001 3.24 (1.08–9.67) 0.035
CR-BSI 0.92 (0.44–1.92) 0.825 0.79 (0.47–1.32) 0.360
Pneumonia 0.37 (0.14–1.00) 0.050 0.28 (0.14–0.59) 0.001 2.15 (0.51–9.04) 0.296
Severe sepsis or septic shock 3.84 (1.85–7.96) <0.001 3.64 (2.17–6.10) <0.001 5.45 (2.14–13.87) <0.001
Retention of foreign body 1.63 (0.40–6.71) 0.500 1.96 (0.62–6.18) 0.250
Charlson’s comorbidity index (per 1-point increment) 0.66 (0.57–0.77) <0.001 0.68 (0.61–0.75) <0.001 1.52 (1.27–1.83) <0.001
Pitt’s bacteremia score (per 1-point increment) 0.77 (0.64–0.93) <0.001 0.76 (0.66–0.87) <0.001 1.23 (0.99–1.54) 0.067
Age (per 1-year increment) 0.96 (0.94–0.98) 0.001 0.97 (0.95–0.98) <0.001 1.02 (1.00–1.05) 0.105
Vancomycin MICs 0.48 (0.20–1.16) 0.103 0.42 (0.23–0.79) 0.007 1.55 (0.52–4.62) 0.433
CR-BSI catheter-related bloodstream infection, IPTW inverse probability of treatment weighted, OR odds ratio, 95 % CI 95 % confidence interval, MIC minimum
inhibitory concentration, NA not available
aThese variables were not available because they displayed perfect marginal homogeneity with respect to each category concerning inappropriate initial empirical
antibiotic therapy
Table 6 Evaluation of the association between inappropriate empirical antibiotic therapy and in-hospital mortality in patients with
healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia
Number P-value OR 95 % CI
LL UL
Model 1 Unmatched sample, no adjustment 345 0.979 1.01 0.64 1.58
Model 2 Unmatched sample with no PS, adjusted for all covariates 345 0.499 0.79 0.40 1.56
Model 3 Unmatched sample with IPTW, adjusted for all covariates 345 0.236 0.75 0.47 1.20
Model 4 PS-matched sample, no adjustment 254 0.984 NAa .
Model 5 PS-matched sample adjusted for all covariates 254 0.988 NAa .
PS propensity score, IPTW inverse probability of treatment weighted, OR odds ratio, 95 % CI 95 % confidence interval, LL lower limit, UL upper limit
aThese variables were not available because they displayed perfect marginal homogeneity with respect to each category concerning inappropriate initial empirical
antibiotic therapy
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There are some potential limitations in our study.
First, the multivariate propensity-matched analysis still
has a residual risk for confounding given the non-
randomized, controlled study design. Second, it should
be acknowledged that culture sampling itself might have
been delayed in some cases due to difficulties in suspect-
ing the presence of MRSAB. Third, different kinds of anti-
biotics used for definitive therapy against MRSA can
affect the clinical outcomes. However, there was no statis-
tical difference in the distribution of definitive antibiotics
in the comparative analyses of empirical antibiotic therapy
or treatment outcomes. Fourth, vancomycin MIC for
MRSA isolates was determined using the thawed, stored
strains in this study, which can lead to an overall decline
in vancomycin MICs measured for the same strains at the
time of isolation. The effects of storage on the vancomycin
MIC of the isolates may be considered confounders [49].
Lastly, this study showed a lack of significant difference in
the hospital mortality between patients who received in-
appropriate or appropriate empirical antibiotics. This may
imply an inconclusive result from the limited sample size,
rather than a lack of any effect of appropriate empirical
antibiotic therapy.
Conclusions
In conclusion, empirical inappropriate antibiotic therapy
was not a significant predictor of mortality in patients
with HA-MRSAB in hospitals with a high prevalence of
MRSA. These findings suggest that it may be safe to
await microbiological results and guide the use of defini-
tive antibiotics in patients suspected of having HA-
MRSAB. Although earlier proper antibiotic prescribing
is usually recommended for bacteremic patients by most
experts, the empirical use of glycopeptides should be
guided by the presence of predictors of MRSAB as well
as the risk factors associated with MRSAB-related
mortality.
Abbreviations
CR-BSI, catheter-related bloodstream infection; HA-MRSAB, healthcare-associated
methicillin-resistant Staphylococcus aureus bacteremia; IPTW, inverse probability
of treatment weighting; IQR, inter-quartile range; MICs, minimum inhibitory
concentrations; MRSA, methicillin-resistant Staphylococcus aureus; MRSAB,




This study was financially supported in part by a grant (A102065) from the
Korean Health 21 R&D project, Ministry for Health, Welfare and Family
Affairs, Republic of Korea, the City of Seoul Grant #10920 and a National
Research Foundation of Korea grant funded by the Korean government
(No. K20902001448-10E0100-03010). The funders had no role in study design,
data collection, data analysis, data interpretation, or writing the report.
Availability of data and materials
The data analyzed in this study can be accessed by sending a request to the
corresponding author, after considering the progress of the ongoing post
hoc analysis and with the approval of the Institutional Review Boards.
Authors’ contributions
YKY performed the data verification, analyzed the data, and drafted the
manuscript. MJK designed the study, and participated in manuscript
revisions. KRP conceived the study. KSY conducted the statistical analysis. JYK
performed the data verification and the integrity of the data. DWP, JWS, HYK,
YSK, CSL, MSL, SYR, HCJ, YJC, CIK, HJC, SSL, SWK, SIK, and ESK contributed
clinical data. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing intersts.
Consent for publication
Not applicable.
Ethics and consent to participate
The study protocol was approved by the Institutional Review Board prior to
starting the study at Korea University Anam Hospital (AN11209-002). As this
observational study required no additional procedure apart from routine
medical practice, the board waived the need for informed consent.
Author details
1Department of Internal Medicine, Korea University College of Medicine,
Seoul, Republic of Korea. 2Department of Internal Medicine, Yonsei University
Wonju College of Medicine, Won Ju, Republic of Korea. 3Department of
Internal Medicine, Chungnam National University Hospital, Daejon, Republic
of Korea. 4Department of Internal Medicine, Chonbuk National University
Medical School, Jeonju, Republic of Korea. 5Department of Internal Medicine,
Kyung Hee University School of Medicine, Seoul, Republic of Korea.
6Department of Internal Medicine, Keimyung University Dongsan Hospital,
Daegu, Republic of Korea. 7Department of Internal Medicine, Chonnam
National University Medical School, Gwangju, Republic of Korea. 8Department
of Internal Medicine, National Cancer Center, Seoul, Republic of Korea.
9Department of Internal Medicine, Sungkyunkwan University School of
Medicine, Seoul, Republic of Korea. 10Department of Internal Medicine, Ewha
Women’s University School of Medicine, Seoul, Republic of Korea.
11Department of Internal Medicine, Hallym University Sacred Heart Hospital,
Anyang, Republic of Korea. 12Department of Internal Medicine, Kyungpook
National University Hospital, Daegu, Republic of Korea. 13Department of
Internal Medicine, Catholic University of Korea, College of Medicine, Seoul,
Republic of Korea. 14Department of Internal Medicine, Seoul National
University Bundang Hospital, Seoul, Republic of Korea. 15Department of
Internal Medicine, Samyook Medical Center, Seoul, Republic of Korea.
16Department of Biostatistics, Korea University College of Medicine, Seoul,
Republic of Korea.
Received: 12 November 2015 Accepted: 8 June 2016
References
1. Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR, Medeiros EA,
et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of
2,563 cases from a prospective nationwide surveillance study. J Clin
Microbiol. 2011;49:1866–71.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB.
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases
from a prospective nationwide surveillance study. Clin Infect Dis.
2004;39:309–17.
3. Hall 2nd RG, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA,
et al. Empiric guideline-recommended weight-based vancomycin dosing
and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a
retrospective cohort study. BMC Infect Dis. 2012;12:104.
4. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A,
Moellering Jr RC. Accessory gene regulator group II polymorphism in
methicillin-resistant Staphylococcus aureus is predictive of failure of
vancomycin therapy. Clin Infect Dis. 2004;38:1700–5.
Yoon et al. BMC Infectious Diseases  (2016) 16:331 Page 10 of 12
5. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site
of infection rather than vancomycin MIC predicts vancomycin treatment
failure in methicillin-resistant Staphylococcus aureus bacteraemia.
J Antimicrob Chemother. 2011;66:2386–92.
6. Rojas L, Bunsow E, Muñoz P, Cercenado E, Rodríguez-Créixems M, et al.
Vancomycin MICs do not predict the outcome of methicillin-resistant
Staphylococcus aureus bloodstream infections in correctly treated patients.
J Antimicrob Chemother. 2012;67:1760–8.
7. Lin SH, Liao WH, Lai CC, Liao CH, Tan CK, Wang CY, et al. Risk factors for
mortality in patients with persistent methicillin-resistant Staphylococcus
aureus bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob
Chemother. 2010;65:1792–8.
8. Liao CH, Chen SY, Huang YT, Hsueh PR. Outcome of patients with
methicillin-resistant Staphylococcus aureus bacteraemia at an Emergency
Department of a medical centre in Taiwan. Int J Antimicrob Agents.
2008;32:326–32.
9. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-
resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality
analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth
microdilution method. BMC Infect Dis. 2010;10:159.
10. Gómez J, García-Vázquez E, Baños R, Canteras M, Ruiz J, Baños V, et al.
Predictors of mortality in patients with methicillin-resistant Staphylococcus
aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy.
Eur J Clin Microbiol Infect Dis. 2007;26:239–45.
11. Fang CT, Shau WY, Hsueh PR, Chen YC, Wang JT, Hung CC, et al. Early
empirical glycopeptide therapy for patients with methicillin-resistant
Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob
Chemother. 2006;57:511–9.
12. Marchaim D, Kaye KS, Fowler VG, Anderson DJ, Chawla V, Golan Y, et al.
Case–control study to identify factors associated with mortality among
patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin
Microbiol Infect. 2010;16:747–52.
13. Rodríguez-Baño J, Millán AB, Domínguez MA, Borraz C, González MP,
Almirante B, et al. Impact of inappropriate empirical therapy for sepsis due
to health care-associated methicillin-resistant Staphylococcus aureus.
J Infect. 2009;58:131–7.
14. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-
resistant Staphylococcus aureus sterile-site infection: The importance
of appropriate initial antimicrobial treatment. Crit Care Med.
2006;34:2069–74.
15. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al.
Influence of vancomycin minimum inhibitory concentration on the
treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2008;46:193–200.
16. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial
antibiotic choice and delayed appropriate treatment on the outcome of
Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2006;25:181–5.
17. McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise Jr TP, et al.
A systematic review of the methods used to assess the association between
appropriate antibiotic therapy and mortality in bacteremic patients.
Clin Infect Dis. 2007;45:329–37.
18. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB.
Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol
Rev. 2012;25:362–86.
19. Lee CH, Chien CC, Liu JW. Timing of initiating glycopeptide therapy for
methicillin-Resistant Staphylococcus aureus bacteremia: the impact on
clinical outcome. Scientific World Journal. 2013;2013:457435.
20. Kim SH, Park WB, Lee KD, Kang CI, Bang JW, Kim HB, et al. Outcome of
inappropriate initial antimicrobial treatment in patients with methicillin-resistant
Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2004;54:489–97.
21. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance
of appropriate empirical antibiotic therapy for methicillin-resistant
Staphylococcus aureus bacteraemia. J Antimicrob Chemother.
2010;65:2658–65.
22. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical
practice guidelines for the diagnosis and management of intravascular
catheter-related infection: 2009 Update by the Infectious Diseases Society of
America. Clin Infect Dis. 2009;49:1–45.
23. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of
health care-associated infection and criteria for specific types of infections
in the acute care setting. Am J Infect Control. 2008;36:309–32.
24. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Joseph L. Harrison’s
principles of Internal Medicine (ed 18). USA: Mc Graw Hill; 2008.
25. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined
comorbidity index. J Clin Epidemiol. 1994;47:1245–51.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classification system. Crit Care Med. 1985;13:818–29.
27. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al.
Enterobacter bacteremia: clinical features and emergence of antibiotic
resistance during therapy. Ann Intern Med. 1991;115:585–90.
28. Rubin DB. Estimating causal effects from large data sets using propensity
scores. Ann Intern Med. 1997;127:757–63.
29. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic
strategies using propensity scores. Ann Intern Med. 2002;137:693–5.
30. Austin PC. An introduction to propensity score methods for reducing the
effects of confounding in observational studies. Multivariate Behav Res.
2011;46:399–424.
31. Sugihara M. Survival analysis using inverse probability of treatment
weighted methods based on the generalized propensity score. Pharm
Stat. 2010;9:21–34.
32. Rosenbaum PR. Design of Observational Studies. New York: Springer; 2010.
33. Lanza ST, Moore JE, Butera NM. Drawing causal inferences using propensity
scores: a practical guide for community psychologists. Am J Community
Psychol. 2013;52:380–92.
34. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC,
et al. Empiric antibiotic therapy for Staphylococcus aureus bacteremia may
not reduce in-hospital mortality: a retrospective cohort study. PLoS One.
2010;5:e11432.
35. Lewis T, Chaudhry R, Nightingale P, Lambert P, Das I. Methicillin-resistant
Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory
characteristics in a tertiary referral center in the UK. Int J Infect Dis.
2011;15:e131–5.
36. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of
delayed antibiotic treatment for hospital-acquired Staphylococcus aureus
bacteremia. Clin Infect Dis. 2003;36:1418–23.
37. Kim JS, Kim HS, Song W, Cho HC, Lee KM, Kim EC. Antimicrobial resistance
profiles of Staphylococcus aureus isolated in 13 Korean hospitals.
Korean J Lab Med. 2004;24:223–9.
38. Voss A, Doebbeling BN. The worldwide prevalence of methicillin-resistant
Staphylococcus aureus. Int J Antimicrob Agents. 1995;5:101–6.
39. Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al.
Clinical characteristics of vancomycin minimum inhibitory concentration of
2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from
patients with bacteremia. J Infect Chemother. 2011;17:52–7.
40. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile
neutropenia in patients with cancer: pros and cons. Clin Infect Dis.
1999;29:503–7.
41. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An
international prospective study of pneumococcal bacteremia: correlation
with in vitro resistance, antibiotics administered, and clinical outcome.
Clin Infect Dis. 2003;37:230–7.
42. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role
of glycopeptides as part of initial empirical treatment of febrile neutropenic
patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis.
2005;5:431–9.
43. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against
Gram-positive infections for febrile neutropenia: systematic review and
meta-analysis of randomized controlled trials. J Antimicrob Chemother.
2005;55:436–44.
44. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A
randomized trial comparing ceftazidime alone with combination antibiotic
therapy in cancer patients with fever and neutropenia. N Engl J Med.
1986;315:552–8.
45. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-
positive infections and the use of vancomycin in 550 episodes of fever
and neutropenia. Ann Intern Med. 1988;108:30–5.
46. Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory
concentration and clinical outcomes in adults with methicillin-resistant
Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis.
2013;17:e93–e100.
47. Mavros MN, Tansarli GS, Vardakas KZ, Rafailidis PI, Karageorgopoulos DE,
Falagas ME. Impact of vancomycin minimum inhibitory concentration on
Yoon et al. BMC Infectious Diseases  (2016) 16:331 Page 11 of 12
clinical outcomes of patients with vancomycin-susceptible Staphylococcus
aureus infections: a meta-analysis and meta-regression. Int J Antimicrob
Agents. 2012;40:496–509.
48. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high
vancomycin minimum inhibitory concentration in methicillin-resistant
Staphylococcus aureus bloodstream infections. Clin Infect Dis.
2011;52:997–1002.
49. Ludwig F, Edwards B, Lawes T, Gould IM. Effects of storage on vancomycin
and daptomycin MIC in susceptible blood isolates of methicillin-resistant
Staphylococcus aureus. J Clin Microbiol. 2012;50:3383–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yoon et al. BMC Infectious Diseases  (2016) 16:331 Page 12 of 12
